Diasorin SpAMIL:DIA +3.13%69 FCF Margin % is 28.05% as of Dec. 2025, which is 31% above its 10-year median of 21.38. GuruFocus rates MIL:DIA with a GF Score™ of 69/100 and a GF Value™ of €90.07 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 95.59% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Diasorin SpA's Free Cash Flow for the
three
months ended in Dec. 2025 was €83 Mil. Diasorin SpA's Revenue for the
three
months ended in Dec. 2025 was €295 Mil. Therefore, Diasorin SpA's FCF Margin % for the quarter that ended in Dec. 2025 was 28.05%.
The historical rank and industry rank for Diasorin SpA's FCF Margin % or its related term are showing as below:
MIL:DIA'
s FCF Margin % Range Over the Past 10 Years
Min: 17.16 Med: 21.38 Max: 28.22
Current: 28.22
During the past 13 years, the highest FCF Margin % of Diasorin SpA was 28.22%. The lowest was 17.16%. And the median was 21.38%.
MIL:DIA's FCF Margin % is ranked better than 95.59% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs MIL:DIA: 28.22
Diasorin SpA FCF Margin % Related Terms
Diasorin SpA FCF Margin % Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:DIA vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (MIL:DIA) has a FCF Margin % of 28.05% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Diasorin SpA and its competitors. This is 31% above median its historical median of 21.38. Over the past decade, Diasorin SpA's FCF Margin % has ranged from 17.16 to 28.22. According to the industry distribution chart, Diasorin SpA ranks #9 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 4.4%.
Is Diasorin SpA's FCF Margin % too high?
Diasorin SpA's current FCF Margin % of 28.05% is 31% above median its 10-year median of 21.38. Over the past 10 years, this metric has ranged from a low of 17.16 to a high of 28.22. Based on the distribution chart, Diasorin SpA ranks #9 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diasorin SpA has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #9 out of 204 companies for FCF Margin %. This places Diasorin SpA in the top 4% of its industry — outperforming the majority of peers. Historically, Diasorin SpA's own FCF Margin % has ranged from 17.16 to 28.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current FCF Margin % is 28.05%, which is 31% above median its own 10-year median of 21.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.07, compared to a current price of €66.48 — trading 26.2% below its estimated fair value. The current FCF Margin % is 28.05%, which is 31% above median its 10-year median of 21.38. Diasorin SpA's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current FCF Margin % is 28.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (MIL:DIA) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €66.48 is trading 26.2% below its estimated GF Value™ of €90.07.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for MIL:DIA:
FCF Margin %: 28.05% (31% above median its 10-year median of 21.38)
GF Value™: €90.07 vs. price of €66.48 (26.2% below fair value)
No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
69GF Score
Get the complete analysis for MIL:DIA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:DIA has been successfully added to your 
